BI 3032950
Alternative Names: BI-3032950Latest Information Update: 06 Oct 2022
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 05 Sep 2022 Preclinical trials in Unspecified in Germany (IV) (NCT05518708)
- 05 Sep 2022 Preclinical trials in Unspecified in Germany (SC) (NCT05518708)
- 29 Aug 2022 Boehringer Ingelheim plans a phase I trial (In volunteers) in September 2022 (IV, SC) (NCT05518708)